Finance

Beta
Lists
302440:KRX
SK Bioscience Co Ltd
₩39,200.00
-0.38%
(-150.00) 1D
Jun 12, 3:30:26 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 302440...
Open
₩39,850
High
₩40,650
Low
₩39,200
Mkt. cap
3.08T
Avg. vol.
159.17K
Volume
0.00
52-wk high
₩61,300
52-wk low
₩37,000
EPS
-₩1,062
Shares outstanding
78.46M
No. of employees
917
Open
₩39,850
High
₩40,650
Low
₩39,200
Mkt. cap
3.08T
Avg. vol.
159.17K
Volume
0.00
52-wk high
₩61,300
52-wk low
₩37,000
EPS
-₩1,062
Shares outstanding
78.46M
No. of employees
917
News stories
From sources across the web
Profile
SK Bioscience is a South Korean biotechnology company that produces vaccines and other products and is a subsidiary of SK Chemicals. Wikipedia
About SK Bioscience Co Ltd
CEOAhn Jae-yong
Employees917
FoundedJul 1, 2018
Headquarters-
SectorBiotechnology
Websiteskbioscience.co.kr
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
161.86B
150.76B
184.19B
168.61B
Cost of goods sold
150.33B
118.04B
179.39B
154.02B
Cost of revenue
150.33B
118.04B
179.39B
154.02B
Research and development expenses
20.24B
19.88B
17.75B
20.98B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
24.53B
27.51B
33.59B
32.09B
Operating expense
48.92B
52.09B
56.40B
59.13B
Total operating expenses
199.25B
170.14B
235.80B
213.15B
Operating income
-37.40B
-19.37B
-51.61B
-44.54B
Other non operating income
3.46B
-637.92M
-1.13B
-364.73M
EBT including unusual items
-35.16B
-15.58B
-21.32B
-47.85B
EBT excluding unusual items
-36.71B
-23.07B
-48.65B
-46.46B
Income tax expense
-18.38B
-36.66B
35.09B
-11.68B
Effective tax rate
52.28%
235.33%
-164.62%
24.42%
Other operating expenses
449.92M
281.98M
532.04M
261.38M
Net income
-16.48B
24.48B
-57.96B
-33.33B
Net profit margin
-10.18%
16.24%
-31.47%
-19.77%
Earnings per share
-210.00
313.00
-740.00
-425.00
Interest and investment income
3.14B
2.75B
6.81B
4.88B
Interest expense
-2.28B
-2.67B
-2.04B
-3.73B
Net interest expenses
859.12M
84.41M
4.77B
1.15B
Depreciation and amortization charges
1.48B
1.15B
1.49B
2.67B
EBITDA
-15.87B
3.25B
-25.91B
-19.11B
Gain or loss from assets sale
371.46M
-547.83M
-30.91B
105.62M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer